AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT

Recruiting now

Conditions studied: Advanced Solid Tumor

In brief

National, retro- and prospective, observational, multicenter clinical research platform to connect clinical and genomic data of patients with advanced (locally advanced, inoperable, or metastatic) solid tumors (excluding NSCLC, SCLC, and mesothelioma) with results from multi-gene next-generation sequencing (NGS) panels (\>30 genes)

Key facts

Study ID

NCT05701150

Run by

AIO-Studien-gGmbH

People needed

3000

Starts

2022-12-08

Expected to finish

2025-12-01

Last updated by the study team

2025-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced (i.e., locally advanced, inoperable, or metastatic) solid tumor, ineligible for curative surgery and/or curative systemic therapy
• Available results of commercial or non-commercial RNA- and/or DNA-based multi-gene NGS panels with >30 genes analyzed; for non-commercial panels a list of all tested genes and multiple gene biomarkers (e.g., tumor mutational burden (TMB), microsatellite status) must be provided
• Age ≥ 18 years
• Signed and dated informed consent form (not applicable for inclusion of deceased patients)

You may not qualify if…

• Diagnosis of NSCLC/SCLC (C34) or mesothelioma (C45)
• NGS results older than two years at the date of patient inclusion

Where it is running

• Praxis für interdisziplinäre Onkologie & Hämatologie — Freiburg im Breisgau, Baden-Wurttemberg, Germany (enrolling)
• Medizinische Fakultät Mannheim der Universität Heidelberg — Mannheim, Baden-Wurttemberg, Germany
• Klinikum der Universität München — München, Bavaria, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.